Potential biopharmaceuticals were developed by the HPA consortium to generate molecules based on different formats, including immunoglobulin G frameworks and the small Affibody scaffold suitable for protein engineering. These Affibody molecules have now entered various human clinical trials, including indications such as cancer, psoriasis, autoimmune diseases, and inflammation. Therapeutic antibodies have been developed in collaboration with the South Korean company AbClon, including therapeutic antibodies for cancer treatment and antibodies with a neutralizing effect on the novel coronavirus, SARS-CoV-2.

Key publication

• Ko BK et al., Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. Mol Oncol. (2015)
  PubMed: 25306393 DOI: 10.1016/j.molonc.2014.09.007

Other selected publications

• Orlova A et al., Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. (2006)
  PubMed: 16618759 DOI: 10.1158/0008-5472.CAN-05-3521

• Löfblom J et al., Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. (2010)
  PubMed: 20388508 DOI: 10.1016/j.febslet.2010.04.014

• Volk AL et al., Stratification of responders towards eculizumab using a structural epitope mapping strategy. Sci Rep. (2016)
  PubMed: 27509843 DOI: 10.1038/srep31365

• Ståhl S et al., Affibody Molecules in Biotechnological and Medical Applications. Trends Biotechnol. (2017)
  PubMed: 28514998 DOI: 10.1016/j.tibtech.2017.04.007

• Hoyer W et al., Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc Natl Acad Sci U S A. (2008)
  PubMed: 18375754 DOI: 10.1073/pnas.0711731105